Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
(1) To evaluate the efficacy of each treatment arm of MK-5172 in combination with peg-IFN and RBV as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy). (2) To evaluate the relative safety and tolerability of the selected doses of MK-5172 in combination with peg-IFN and RBV.
Critère d'inclusion
- Chronic hepatitis C virus infection